FDA Warning Letter: Wholesale Peptide Reprimanded

United States: On June 17, 2026, the U.S. Food and Drug Administration (FDA) sent an official warning letter to the peptide supplier Wholesale Peptide in Florida. The products "Prostamax" and "Gonadorelin," which were marketed as unapproved new drugs, are at the center of the complaint. According to PeptideKnow (2026)^[9], the agency cites inadmissible therapeutic claims as well as structure and function claims on the website and requires a response within 15 business days. The case illustrates the FDA's strict approach to sellers who market peptides with therapeutic claims.

Key facts about the FDA warning letter to Wholesale Peptide

• The FDA issued a warning letter (MARCS-CMS 729447) to Wholesale Peptide on June 17, 2026, because Prostamax and Gonadorelin were classified as unapproved drugs.
• The agency cites unlawful disease claims as well as structure and function claims on the supplier's website, as reported by PeptideKnow (2026)^[9].
• Wholesale Peptide is required to respond to the letter within 15 business days to avert further regulatory or legal action.
• The case shows that "Research Use Only" notices do not offer protection from FDA action when the website suggests therapeutic use.

What exactly does the FDA accuse Wholesale Peptide of?

The FDA accuses Wholesale Peptide of the unlawful distribution of Prostamax and Gonadorelin as unapproved new drugs. Because these products were advertised with medical efficacy claims without regulatory review, they violate applicable law. According to PeptideKnow (2026)^[9], the agency found during a review in May 2026 that the peptide hormone Gonadorelin in particular was marketed with claims about influencing sex hormone levels. Such health-related claims legally make a product a drug that requires appropriate approval.

What consequences does the supplier face?

If the violations are not corrected, the supplier faces serious legal consequences such as seizures or injunctions. Wholesale Peptide must provide a written explanation within 15 business days of how the deficiencies will be remedied. According to the FDA (2026)^[2], such a warning letter marks the agency's first formal step before harsher measures such as import bans or court proceedings are initiated. For you as a buyer, such a warning letter is a clear signal of increased risk with this supplier.

How does this case fit into the current FDA strategy?

This warning letter is part of a comprehensive FDA offensive against the unregulated peptide market. As early as April 7, 2026, seven online shops were warned for selling retatrutide and other GLP-1 peptides, as reported by PeptideKnow (2026)^[7]. In mid-June 2026, 25 warning letters were also sent to various telehealth providers. The Wholesale Peptide case shows that the FDA also intervenes consistently with peptides outside the weight-loss segment. According to PeptideKnow (2026)^[9], the agency explicitly emphasizes that "Research Use Only" labels do not negate the actual intent of therapeutic use in humans.

What does this mean for you?

If you buy peptides, you should check in advance whether the supplier has already been sanctioned or warned by authorities. An official warning letter is a strong indication of a lack of credibility and quality control. Use the Vendor Radar on our protection page to check, and learn about the properties of the respective substances in the Peptide Library. Unapproved drugs pose significant health risks because their purity and safety are not guaranteed.

This article is for information only and is not medical advice. For health-related questions, consult a doctor.